Standard Biotools Ownership

LAB Stock  USD 1.45  0.03  2.03%   
Standard Biotools shows a total of 384.57 Million outstanding shares. The majority of Standard Biotools outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Standard Biotools to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Standard Biotools. Please pay attention to any change in the institutional holdings of Standard Biotools as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Standard Biotools in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Standard Biotools, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.

Standard Stock Ownership Analysis

About 77.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.4. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Standard Biotools has Price/Earnings To Growth (PEG) ratio of 0.31. The entity recorded a loss per share of 0.39. The firm had not issued any dividends in recent years. Standard Biotools had a split on the 6th of December 2001. Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. Standard Biotools operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 615 people. To find out more about Standard Biotools contact Michael Egholm at 650 266 6000 or learn more at https://www.standardbio.com.

Standard Biotools Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Standard Biotools insiders, such as employees or executives, is commonly permitted as long as it does not rely on Standard Biotools' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Standard Biotools insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Casdin Partners Master Fund, L.p. over a week ago
Acquisition by Casdin Partners Master Fund, L.p. of 150000 shares of Standard Biotools at 1.4468 subject to Rule 16b-3
 
Casdin Partners Master Fund, L.p. over a week ago
Acquisition by Casdin Partners Master Fund, L.p. of 125000 shares of Standard Biotools at 1.4201 subject to Rule 16b-3
 
Casdin Partners Master Fund, L.p. over two weeks ago
Acquisition by Casdin Partners Master Fund, L.p. of 150000 shares of Standard Biotools at 1.4325 subject to Rule 16b-3
 
Casdin Partners Master Fund, L.p. over three weeks ago
Acquisition by Casdin Partners Master Fund, L.p. of 450000 shares of Standard Biotools at 1.3028 subject to Rule 16b-3
 
Casdin Partners Master Fund, L.p. over three weeks ago
Acquisition by Casdin Partners Master Fund, L.p. of 250000 shares of Standard Biotools at 1.2392 subject to Rule 16b-3
 
Casdin Partners Master Fund, L.p. over a month ago
Acquisition by Casdin Partners Master Fund, L.p. of 375000 shares of Standard Biotools at 1.1889 subject to Rule 16b-3
 
Casdin Partners Master Fund, L.p. over a month ago
Acquisition by Casdin Partners Master Fund, L.p. of 225000 shares of Standard Biotools at 1.1234 subject to Rule 16b-3
 
Casdin Partners Master Fund, L.p. over a month ago
Acquisition by Casdin Partners Master Fund, L.p. of 100000 shares of Standard Biotools at 1.2892 subject to Rule 16b-3
 
Casdin Partners Master Fund, L.p. over three months ago
Acquisition by Casdin Partners Master Fund, L.p. of 100000 shares of Standard Biotools at 1.2892 subject to Rule 16b-3
 
Casdin Partners Master Fund, L.p. over three months ago
Acquisition by Casdin Partners Master Fund, L.p. of 250000 shares of Standard Biotools at 1.2774 subject to Rule 16b-3
 
Hanjoon Kim over three months ago
Disposition of 127 shares by Hanjoon Kim of Standard Biotools at 1.27 subject to Rule 16b-3
 
Casdin Partners Master Fund, L.p. over three months ago
Acquisition by Casdin Partners Master Fund, L.p. of 250000 shares of Standard Biotools at 2.187 subject to Rule 16b-3

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.